Qiagen Nv Intrinsic Stock Value – Retain QIAGEN Stock Now for Positive Returns
January 2, 2024
☀️Trending News
QIAGEN NV ($NYSE:QGEN) is a global market leader in providing innovative and easy-to-use sample to insight solutions for molecular testing. Their solutions are used by healthcare providers, pharmaceutical companies, and academic institutions to help improve the performance of their laboratories and develop new diagnostics, treatments, and therapies. With their strong network of partners and a wide range of products, QIAGEN is well-positioned to continue to provide value to its shareholders. Now is an ideal time to retain QIAGEN shares. The company’s earnings per share (EPS) and revenue have grown over the past few years, while their share price has remained relatively stable.
The stock has recently experienced a slight dip, making it an attractive opportunity for investors looking to buy in at a discounted rate. Furthermore, the long-term trend of the company’s stock has been up over the past few years, indicating that it could be a good option for those who want to hold their stock for positive returns. With a strong network of partners and products, plus a recent dip in its stock price, investing in QIAGEN shares now could prove to be a lucrative decision for those looking to achieve good returns in the long run.
Price History
QIAGEN NV stock opened at $43.4 and closed at $43.4 on Friday, representing a small decline of 0.3% from last closing price of 43.6. Despite this minor dip, it is recommended to retain the QIAGEN NV stock in the current market as upbeat sentiments in the sector and generally positive market conditions suggest positive returns in the near future. QIAGEN NV is one of the leading players in the molecular diagnostics market and a sound investment opportunity at this time. Live Quote…
About the Company
Income Snapshot
Below shows the total revenue, net income and net margin for Qiagen Nv. More…
| Total Revenues | Net Income | Net Margin |
| 1.95k | 332.48 | 18.3% |
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Qiagen Nv. More…
| Operations | Investing | Financing |
| 432.41 | -153.73 | -972.76 |
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Qiagen Nv. More…
| Total Assets | Total Liabilities | Book Value Per Share |
| 5.91k | 2.21k | 16.19 |
Key Ratios Snapshot
Some of the financial key ratios for Qiagen Nv are shown below. More…
| 3Y Rev Growth | 3Y Operating Profit Growth | Operating Margin |
| 4.5% | -3.5% | 24.2% |
| FCF Margin | ROE | ROA |
| 14.1% | 8.1% | 5.0% |
Analysis – Qiagen Nv Intrinsic Stock Value
GoodWhale recently conducted an analysis of QIAGEN NV’s wellbeing, and our Valuation Line has determined the intrinsic value of QIAGEN NV’s share to be around $53.6. However, at the time of writing, the stock is trading at $43.4, which is a fair price that is undervalued by 19.1%. This suggests that there may be an opportunity to buy QIAGEN NV stock at a competitive rate. We believe that this stock has the potential for a strong return on investment in the short-term with a minimal level of risk. More…
Peers
In the market for molecular diagnostics, Qiagen NV faces competition from BioMerieux SA, Agilent Technologies Inc, and Diasorin SpA. These companies offer a range of products and services that are similar to Qiagen NV’s offerings.
– BioMerieux SA ($OTCPK:BMXMF)
Found in 1963, BioMérieux is a French multinational corporation that produces medical diagnostic systems. The company is headquartered in Lyon and has over 11,000 employees in 43 countries.
In terms of market cap, BioMérieux is a large company with a market cap of over 10 billion as of 2022. The company’s return on equity is also strong, at 13.56%.
BioMérieux produces medical diagnostic systems that are used in a variety of settings, including hospitals, clinics, and laboratories. The company’s products are used to diagnose a wide range of conditions, including infections, cancer, and cardiovascular disease.
– Agilent Technologies Inc ($NYSE:A)
Agilent Technologies Inc is a leading global provider of scientific instruments, software, services, and solutions. The company serves the life sciences, diagnostics, and applied chemical markets. Agilent has a market cap of $37.28B as of 2022 and a ROE of 19.27%. The company’s products and services are used by customers in a wide range of industries, including academic and government institutions, pharmaceutical and biotechnology companies, and commercial laboratories.
– Diasorin SpA ($LTS:0GZX)
Diasorin SpA is a publicly traded company with a market capitalization of 6.94B as of 2022. The company has a strong return on equity of 17.96%. Diasorin is engaged in the research, development, and manufacture of diagnostic tests for a number of diseases and conditions. The company’s products are sold in over 60 countries worldwide.
Summary
QIAGEN NV is a Netherlands-based biotechnology company that provides sample to insight solutions for molecular diagnostics, applied testing and academic research. Analysts are generally bullish on the company, citing its strong market position, wide range of products, and established customer base as key factors. In addition, the company has a strong dividend yield and cash flow generating capability which could make it attractive for dividend investors. Overall, QIAGEN appears to be a solid long-term investment.
